Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

Serotonin-norepinephrine reuptake inhibitors are antidepressants that block the reuptake of both serotonin and norepinephrine, combining a dual-monoamine action in a single molecule while generally lacking the broad receptor binding of older tricyclic agents. They occupy a middle position between the serotonin-selective SSRIs and the multi-target tricyclics.

Definition

SNRIs are antidepressants that inhibit both the serotonin transporter and the norepinephrine transporter, increasing the synaptic availability of both monoamines, typically without the extensive off-target receptor binding of tricyclic antidepressants.

Scope

This entry covers the dual-transporter mechanism that defines the SNRI class and its comparative pharmacological position relative to SSRIs and tricyclics. It treats the material as pharmacology reference rather than prescribing guidance.

Core questions

• How does dual reuptake inhibition distinguish SNRIs from SSRIs?
• How does the relative potency at SERT versus NET vary across the class?
• How do SNRIs compare with other antidepressants in efficacy and acceptability?

Key concepts

• Serotonin transporter (SERT) and norepinephrine transporter (NET)
• Dual reuptake inhibition
• Dose-dependent noradrenergic effect
• Comparative position between SSRIs and tricyclics

Mechanisms

SNRIs inhibit two SLC6-family transporters, SERT and NET, raising synaptic levels of both serotonin and norepinephrine. The relative affinity for the two transporters differs across agents, and for some the noradrenergic component becomes more prominent at higher exposures. By targeting transporters rather than a wide range of receptors, the class avoids much of the anticholinergic and antihistaminergic burden associated with tricyclic antidepressants.

Clinical relevance

SNRIs are studied as one of the dual-mechanism antidepressant options, and their transporter pharmacology is the basis for comparing them with serotonin-selective and multi-target agents. This description is for reference only and is not dosing, selection, or individualised treatment advice.

Evidence & guidelines

Comparative effectiveness research, including large network meta-analyses, has examined SNRIs alongside SSRIs and other antidepressants for acute major depression, finding the active agents broadly effective with modest differences in efficacy and acceptability.

History

SNRIs were developed to reproduce the dual serotonergic and noradrenergic action of tricyclic antidepressants while avoiding their broad receptor binding. Venlafaxine, introduced in the 1990s, was an early representative, and comparative trials against SSRIs such as fluoxetine helped characterise the class.

Seminal works

• kristensen-2011
• cipriani-2018

Frequently asked questions

How do SNRIs differ from SSRIs?

SNRIs block both the serotonin and norepinephrine transporters, whereas SSRIs act preferentially at the serotonin transporter alone.

Why is the noradrenergic effect sometimes described as dose-dependent?

For some SNRIs the affinity for the serotonin transporter is higher than for the norepinephrine transporter, so meaningful noradrenergic reuptake inhibition becomes more prominent at higher exposures.